Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Authors Ian Hamilton-Craig, Karam Kostner, David Colquhoun, et al

Published Date November 2010 Volume 2010:6 Pages 1023—1037

DOI http://dx.doi.org/10.2147/VHRM.S13496

Published 10 November 2010

Ian Hamilton-Craig1, Karam Kostner2, David Colquhoun2, Stan Woodhouse2
1Griffith University School of Medicine, Southport, Queensland, Australia; 2University of Queensland, Brisbane, Queensland, Australia

Abstract: High-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or heFH. These studies have shown the combination to be both effective and safe in the short to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective and safe in combination with statin therapy for children and adolescents with heFH. Effective statin–ezetimibe combination therapy is capable of achieving near-normal lipid profiles in heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and improved life expectancy resulting predominantly from reduction in levels of low-density lipoprotein cholesterol. There are few data to support a pleiotropic action of ezetimibe with regard to CVD benefit, unlike therapy with statins. No serious and unexpected clinical adverse effects of combination statin–ezetimibe therapy have emerged till date, although data are limited in children and adolescents, for whom longer-term studies are required. Recent data suggesting possible proatherogenic effects of ezetimibe require confirmation. One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH.

Keywords: familial hypercholesterolemia, ezetimibe, statin, combination therapy, low-density lipoprotein cholesterol

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Multifunction hexagonal liquid-crystal containing modified surface TiO2 nanoparticles and terpinen-4-ol for controlled release

Manaia EB, Kaminski RCK, Oliveira AG, CorrĂȘa MA, Chiavacci LA

International Journal of Nanomedicine 2015, 10:811-819

Published Date: 22 January 2015

Differentiation between chalazion and sebaceous carcinoma by noninvasive meibography

Nemoto Y, Arita R, Mizota A, Sasajima Y

Clinical Ophthalmology 2014, 8:1869-1875

Published Date: 18 September 2014

Development and characterization of magnetic iron oxide nanoparticles with a cisplatin-bearing polymer coating for targeted drug delivery

Unterweger H, Tietze R, Janko C, Zaloga J, Lyer S, Dürr S, Taccardi N, Goudouri OM, Hoppe A, Eberbeck D, Schubert DW, Boccaccini AR, Alexiou C

International Journal of Nanomedicine 2014, 9:3659-3676

Published Date: 5 August 2014

Corrigendum

Jalil MA, Moongfangklang M, Innate K, Mitatha S, Ali J, Yupapin PP

International Journal of Nanomedicine 2012, 7:3279-3280

Published Date: 29 June 2012

The use of amniotic membrane in trabeculectomy for the treatment of primary open-angle glaucoma: a prospective study

Stavrakas P, Georgopoulos G, Milia M, Papaconstantinou D, Bafa M, Stavrakas E, Moschos M

Clinical Ophthalmology 2012, 6:205-212

Published Date: 2 February 2012

Corrigendum

Nelson DA, Ruf A, Oaknin J, Burgansky-Eliash Z, Barash H, Izhaky D, Loewenstein A, Barak A, Bartov E, Rock T, Grinvald A

Clinical Ophthalmology 2011, 5:1317-1318

Published Date: 15 September 2011

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011

Risk factors associated with methamphetamine use and heart failure among Native Hawaiians and other Pacific Island peoples

Marjorie K Mau, Karynna Asao, Jimmy Efird, Erin Saito, Robert Ratner, et al

Vascular Health and Risk Management 2009, 5:45-52

Published Date: 7 December 2008